Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

Category Primary study
JournalEuropean Journal of Cancer
Year 2015
This article has no abstract
Epistemonikos ID: 6441a0d104695db42f915c772d22778135a71a32
First added on: Feb 07, 2025